Mirikizumab in ulcerative colitis: real-world evidence from an international two-center retrospective cohort study.

ABSTRACT:

Background

Mirikizumab is a first-in-class IL-23p19 inhibitor, which is approved for the treatment of adults with moderate to severe ulcerative colitis (UC).

Objectives

We aimed to assess the effectiveness and safety of mirikizumab in moderate to severe UC in a real-world cohort from two inflammatory bowel disease referral centers.

Design

This was a two-center international retrospective observational cohort study.

Methods

This study aimed to assess the effectiveness and safety of mirikizumab for 12 weeks of induction. Clinical response and remission were defined as a reduction in the Simple Clinical Colitis Activity Index (SCCAI) of ⩾3 points, and SCCAI ⩽ 2, respectively. The primary outcome was the clinical remission rates after 12 weeks of induction.

Resu

SUBMITTER: Levartovsky A 

PROVIDER: S-EPMC12602953 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature